Abstract:One of the major applications of generative models for drug discovery targets the lead-optimization phase. During the optimization of a lead series, it is common to have scaffold constraints imposed on the structure of the molecules designed. Without enforcing such constraints, the probability of generating molecules with the required scaffold is extremely low and hinders the practicality of generative models for de novo drug design. To tackle this issue, we introduce a new algorithm, named SAMOA (Scaffold Constrained Molecular Generation), to perform scaffold-constrained in silico molecular design. We build on the well-known SMILES-based Recurrent Neural Network (RNN) generative model, with a modified sampling procedure to achieve scaffold-constrained generation. We directly benefit from the associated reinforcement learning methods, allowing to design molecules optimized for different properties while exploring only the relevant chemical space. We showcase the method's ability to perform scaffold-constrained generation on various tasks: designing novel molecules around scaffolds extracted from SureChEMBL chemical series, generating novel active molecules on the Dopamine Receptor D2 (DRD2) target, and finally, designing predicted actives on the MMP-12 series, an industrial lead-optimization project.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c01015?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c01015</a>.Availability of data used to train models and run experiments, algorithmic description of naive policy masking (Algorithm S1), algorithmic description of hill-climbing (Algorithm S2), examples of molecules obtained after sampling the core of fexofenadine (Figure S1 for sampled molecules, Figure S2 for the original molecule), examples of molecules obtained after replacing the ring system of fexofenadine (Figure S3), distributions of ClogP, Molecular Weight, QED and SAS for reference molecules, molecules where a branched decoration was sampled, and molecules where the core was sampled (Figure S4), the 17 validation scaffolds from SureChEMBL (Figure S5), histograms of Tanimoto similarities between generated molecules for each of the DRD2 scaffolds (Figure S6), and unicity of sampled decorations for each open positions of the DRD2 scaffolds (Figure S7) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01015/suppl_file/ci0c01015_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Generation of Rational Drug-Like Molecular Structures Through a Multiple-Objective Reinforcement Learning Framework

Multi-objective molecular generation via clustered Pareto-based reinforcement learning

De novo drug design using reinforcement learning with graph-based deep generative models

Molecular generation strategy and optimization based on A2C reinforcement learning in de novo drug design

Widely Used and Fast De Novo Drug Design by a Protein Sequence-Based Reinforcement Learning Model

Multi-Objective De Novo Drug Design with Conditional Graph Generative Model

De novo Drug Design using Reinforcement Learning with Multiple GPT Agents

De novo drug design by iterative multiobjective deep reinforcement learning with graph-based molecular quality assessment

DrugEx V2: De Novo Design of Drug Molecules by Pareto-based Multi-Objective Reinforcement Learning in Polypharmacology

LS-MolGen: Ligand-and-Structure Dual-Driven Deep Reinforcement Learning for Target-Specific Molecular Generation Improves Binding Affinity and Novelty.

Electron-density informed effective and reliable de novo molecular design and lead optimization with ED2Mol

Scaffold-Constrained Molecular Generation

Molecular De Novo Design through Deep Reinforcement Learning

De Novo Drug Design by Multi-Objective Path Consistency Learning with Beam A∗ Search

Enhancing Molecular Design through Graph-based Topological Reinforcement Learning

LS-MolGen: Ligand-and-Structure Dual-driven Deep Reinforcement Learning for Target-specific Molecular Generation Improves Binding Affinity and Novelty

Genetic Algorithm-Based Receptor Ligand: A Genetic Algorithm-Guided Generative Model to Boost the Novelty and Drug-Likeness of Molecules in a Sampling Chemical Space.

Utilizing reinforcement learning for de novo drug design

<i>De novo</i> generation of dual-target ligands using adversarial training and reinforcement learning

Diversity oriented Deep Reinforcement Learning for targeted molecule generation

De novo generation of dual-target ligands using adversarial training and reinforcement learning